X
[{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Begins Patient Dosing in Phase 2 Trial of IBI302 to Treat Neovascular Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing Senolytic Drug Candidate UBX1325","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascentage Pharma"},{"orgOrder":0,"company":"VivaVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VVN539 Met Primary Study Endpoints in US Phase IIa Clinical Study for The Treatment of Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"VivaVision"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
VVN539 Ophthalmic Solution is a first-in-class small molecule for the treatment of glaucoma. It acts directly at trabecular meshwork, increases the outflow of aqueous humor for the treatment of with primary open angle glaucoma.
Lead Product(s):
VVN539
Therapeutic Area: Ophthalmology
Product Name: VVN539
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 04, 2023
Details:
UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting. UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma.
Lead Product(s):
UBX1325
Therapeutic Area: Ophthalmology
Product Name: UBX1325
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Unity Biotechnology
Deal Size: $2.0 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
July 28, 2021
Details:
IBI302 has ability to inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation. The primary objective of the study is to evaluate the efficacy and safety of IBI302 in the treatment of nAMD.
Lead Product(s):
IBI302
Therapeutic Area: Ophthalmology
Product Name: IBI302
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 30, 2021